Stock BNTC BENITEC BIOPHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Benitec Biopharma Inc.

Equities

BNTC

US08205P2092

Real-time Estimate Cboe BZX
Other stock markets
 03:43:25 2024-05-15 pm EDT 		5-day change 1st Jan Change
8.67 USD +2.85% Intraday chart for Benitec Biopharma Inc. -0.81% +165.33%
May. 13 Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Apr. 22 Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
AQ
Benitec Biopharma : Releases Third Quarter 2024 Financial Results and Provides Operational Update - Form 8-K
PU
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
AQ
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors
CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
MT
Top Midday Gainers
MT
Top Premarket Gainers
MT
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
AQ
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
CI
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
AQ
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
AQ
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
AQ
Benitec Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
JMP Securities Adjusts Benitec Biopharma's Price Target to $8 From $6, Keeps Market Outperform Rating
MT
Benitec Biopharma Doses First Participant in Trial of Treatment for Oculopharyngeal Muscular Dystrophy
MT
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
AQ
Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
CI
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
AQ
Earnings Flash (BNTC) BENITEC BIOPHARMA Posts Q1 Revenue $0M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BNTC Stock
  4. News Benitec Biopharma Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW